# 2026 Review: Cannabinoids in Managing MS Spasticity > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabinoids-ms-spasticity-2026-review/ > **Published:** 2026-08-08T22:30:01-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:47:50-04:00 > **Clinical Summary:** Patient-reported relief and objective measures disagree in MS spasticity research. A four-step frame for reading those studies honestly. --- CED Clinical Relevance #88 [Cannabis Science](https://cedclinic.com/biphasic-effects-of-cannabis/) Evidence Report A newly published 2026 systematic review and network meta-analysis of 27 randomized trials with >3,000 patients is highly relevant to MS [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/). THC:CBD extracts showed modest spasticity benefit, but low evidence certainty, substantial heterogeneity, and frequent use of patient-reported outcomes require careful clinical interpretation. Clinical Insight | CED Clinic [‘This 2026 systematic review and network meta-analysis synthesizes 27 randomized controlled trials involving over 3,000 patients with multiple sclerosis spasticity. It provides the most current evidence synthesis available on cannabinoids for MS-related muscle stiffness. The review confirms modest benefits of THC:CBD extracts compared to placebo while emphasizing low certainty of evidence, substantial heterogeneity across trials, variable patient responses, and the critical importance of adjunctive use with realistic patient expectations. The findings support structured clinical assessment and safety monitoring when considering cannabinoids for patients whose spasticity is inadequately controlled by conventional therapies.’] Systematic ReviewMultiple SclerosisCannabinoidsSpasticity ManagementEvidence Synthesis Audience Healthcare providers, people with MS, caregivers Primary Topic Multiple Sclerosis | Spasticity | Cannabis | Cannabinoids Source [Read the full source](https://pubmed.ncbi.nlm.nih.gov/42543771/) Table of Contents - [Reading the 2026 MS Spasticity Review Without Overreaching](#Reading_the_2026_MS_Spasticity_Review_Without_Overreaching) - [How to Read This Systematic Review](#How_to_Read_This_Systematic_Review)[Four Steps to Interpret the Findings](#Four_Steps_to_Interpret_the_Findings) - [The Same Study Can Mean Different Things Depending on the Question Being Asked](#The_Same_Study_Can_Mean_Different_Things_Depending_on_the_Question_Being_Asked)[What This Review Means for Your MS Care](#What_This_Review_Means_for_Your_MS_Care) - [Evidence-Based Spasticity Management in MS](#Evidence-Based_Spasticity_Management_in_MS) - [Why Low Evidence Certainty Matters](#Why_Low_Evidence_Certainty_Matters) - [How to Strengthen the Evidence Base](#How_to_Strengthen_the_Evidence_Base) - [Operationalizing This Evidence in Clinical Practice](#Operationalizing_This_Evidence_in_Clinical_Practice) - [Integrating Cannabis into MS Care Guidelines](#Integrating_Cannabis_into_MS_Care_Guidelines) - [Who Benefits and Who Faces Barriers](#Who_Benefits_and_Who_Faces_Barriers) - [Patient-Centered Priorities in Spasticity Care](#Patient-Centered_Priorities_in_Spasticity_Care) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## Reading the 2026 MS Spasticity Review Without Overreaching A 2026 systematic review of 27 randomized trials in >3,000 MS patients found modest spasticity improvements with THC:CBD extracts, but evidence certainty remains low. What This Study Teaches Us [‘How to interpret systematic reviews in cannabis research’, ‘Why evidence certainty matters in clinical decision-making’, ‘How to use cannabis adjunctively in MS spasticity care’] Why This Matters Multiple sclerosis spasticity affects up to 80 percent of people with MS and significantly impacts quality of life. This review provides the most current evidence synthesis on cannabis as an adjunctive therapy. Study Snapshot Study Type Systematic review and meta-analysis of 27 randomized controlled trials Sample Size Over 3,000 patients with MS-related spasticity Interventions THC:CBD extracts, isolated cannabinoids, and other cannabis formulations vs. placebo Primary Outcome Patient-reported spasticity reduction Main Finding THC:CBD extracts reduced spasticity (MD -0.82; 95% CI -1.24 to -0.40) with low certainty of evidence Evidence Quality LOW (GRADE rating) due to heterogeneity and bias risks Clinical Significance Modest effect size; adjunctive use with safety monitoring recommended Clinical Bottom Line Cannabinoids may help some MS patients with inadequately controlled spasticity, but they should remain adjunctive to conventional therapies and used within a structured clinical framework with appropriate monitoring. What Researchers Reviewed Hamm-Buiar and colleagues conducted a systematic review and network meta-analysis of 27 randomized controlled trials evaluating cannabinoids for MS-related spasticity. The analysis included over 3,000 participants and examined multiple intervention types: THC:CBD extracts, other cannabis extracts, isolated cannabinoids (natural or synthetic), and smoked cannabis. Searches covered PubMed, EMBASE, and LILACS through December 2025. Risk of bias was assessed using the RoB 2 tool, and evidence certainty was graded using GRADE and CINeMA. Key Efficacy Findings In the pairwise meta-analysis of 7 studies, THC:CBD extracts reduced patient-reported spasticity compared to placebo with a mean difference of -0.82 on the assessment scale (95% CI -1.24 to -0.40). The network meta-analysis confirmed the superiority of THC:CBD combinations. However, heterogeneity across studies was substantial (I² = 53%), suggesting that benefits varied considerably between trials. Effects were modest in absolute terms. While statistically significant, the clinical meaning of a 0.82-point improvement depends on the scale used and individual patient values. Safety and Adverse Events Adverse events were frequent across the trials but were mostly mild to moderate in severity. Serious adverse events were rare. Common side effects included dizziness, drowsiness, dry mouth, and cognitive effects. The frequency and type of adverse events varied depending on the cannabinoid preparation and dose. No unexpected safety signals emerged, but the evidence was not sufficient to define optimal dosing or identify which MS patients would tolerate cannabinoids best. Evidence Quality and Certainty The certainty of evidence was graded as LOW using GRADE criteria. This reflects clinical and methodological heterogeneity across the included trials. Variability in spasticity measurement tools, cannabinoid formulations, doses, and treatment durations made direct comparisons difficult. Patient populations differed in disease severity and prior treatments. Most trials were small and sponsored by cannabinoid manufacturers, which raises questions about selection bias. Blinding and allocation concealment were not consistently reported. Clinical Interpretation The authors concluded that cannabinoids provide modest improvements in patient-reported spasticity in MS but should be considered cautiously as adjunctive therapy with appropriate safety monitoring. THC:CBD extracts appear superior to other cannabinoid preparations, but the low evidence certainty and modest effect size do not support them as first-line therapy. Better outcome measures (objective spasticity assessment, functional mobility, quality of life) and longer follow-up periods are needed to clarify the true clinical value of cannabinoids in MS spasticity. How Strong Is This Evidence? This was a systematic review of 27 randomized controlled trials with over 3,000 participants, using standardized risk-of-bias assessment (RoB 2 tool) and GRADE certainty of evidence assessment. Network meta-analysis allowed comparison across multiple cannabinoid preparations and formulations. Where This Paper Deserves Skepticism The certainty of evidence is LOW due to substantial clinical and methodological heterogeneity. Trials used different spasticity measurement tools, cannabinoid formulations, and doses. Many trials were industry-sponsored. Objective measures of spasticity were rarely used; most evidence comes from patient-reported outcomes, which are subject to placebo effects and expectations. What This Paper Does Not Show The review does not prove that cannabinoids are effective for all MS patients; show which cannabinoid formulation is optimal; establish ideal dosing; demonstrate that cannabinoids work better than established MS antispasticity medications; prove that long-term use is safe; or justify using cannabinoids as monotherapy. How This Fits With the Broader Clinical Conversation MS-related spasticity affects up to 80 percent of people with MS and significantly impacts quality of life. Established treatments include physical therapy, baclofen, tizanidine, and botulinum toxin injections. There is substantial patient interest in [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/) for spasticity, partly due to limited efficacy or tolerability of conventional medications and to cultural narratives about [cannabis benefits](https://cedclinic.com/cannabis-and-sexuality-benefits-intimacy/). This systematic review provides the most current synthesis of evidence but confirms that cannabinoids should remain adjunctive, not replace established therapies, and should be used within a structured clinical framework. Dr. Caplan’s Take *I would interpret this review as confirming that cannabinoids have a modest place in MS care for select patients whose spasticity is inadequately controlled by conventional approaches.* *The 0.82-point improvement is real and statistically significant but is not transformative. For some patients, even modest relief is valuable; for others, the side-effect burden may not justify the benefit.* *The low evidence certainty reflects genuine methodological challenges in cannabis research—heterogeneous formulations, inconsistent dosing, and patient expectations all complicate the picture.* *My clinical practice reflects this: I ask about spasticity impact, discuss realistic expectations, ensure conventional therapies are optimized, document the specific product and dose, and monitor for both benefit and adverse effects.* What a Careful Reader Should Take Away Cannabinoids may modestly improve MS spasticity in some patients, but low evidence quality and modest effect size do not support use outside a structured clinical framework with realistic expectations, safety monitoring, and optimization of conventional therapies first. Evidence Interpretation Guide ## How to Read This Systematic Review Systematic reviews synthesize many trials to answer a specific question about treatment efficacy and safety. This review asked: Do cannabinoids reduce MS spasticity? The answer is yes, but modestly, with low certainty, and most clearly for THC:CBD extracts. ### Four Steps to Interpret the Findings **Understand what was measured**Most evidence comes from patient-reported spasticity scales, not objective measures of muscle tone. Patient expectations and placebo effects influence self-reported outcomes. **Compare effect sizes to clinical relevance**A mean difference of -0.82 points is statistically significant but clinically modest. The significance of this improvement varies by individual and by scale used. **Note the evidence quality**LOW certainty means results are based on trials with significant limitations (bias risk, heterogeneity, industry sponsorship). Confidence in the finding is not high. **Place in clinical context**Cannabinoids join, not replace, conventional spasticity management. Optimize physical therapy, baclofen, tizanidine, and other established approaches first. The Research Question Do cannabinoids reduce MS-related spasticity and are they safe? The Patient Question Could cannabis help my MS muscle stiffness if my regular medications aren’t working well enough? The Bottom Line Possibly, if your spasticity is truly refractory to conventional therapy, but benefits are modest and should be monitored carefully. CED Perspective Lens ## The Same Study Can Mean Different Things Depending on the Question Being Asked Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses. Lens Overview Eight clinical and research perspectives help interpret how to use this evidence in practice. #### What This Review Means for Your MS Care Cannabis may help some people’s spasticity but is not a guaranteed solution. In the trials, the average improvement was real but modest. If conventional medications work for you, there is no reason to add cannabis. If they are inadequate or not tolerated, cannabis is worth discussing with your neurologist within a structured plan. Lens takeaway Realistic expectations and medical supervision support safer, more effective use. #### Evidence-Based Spasticity Management in MS This review provides the best available synthesis but confirms cannabinoids should remain adjunctive. Optimize PT, baclofen, tizanidine, and botulinum toxin first. If considering cannabinoids, use THC:CBD extracts over other formulations, document the product and dose, establish a specific outcome measure, and set a trial duration with a clear reassessment date. Lens takeaway Structured, evidence-informed cannabinoid use fits into comprehensive MS spasticity management. #### Why Low Evidence Certainty Matters Many trials were small, industry-sponsored, and used different measurement tools. Heterogeneity across trials is substantial, meaning results varied widely. Patient-reported outcomes are susceptible to placebo effects and expectations, which are particularly strong in [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/). Lens takeaway The modest benefit could reflect genuine drug effect, placebo response, or publication bias. #### How to Strengthen the Evidence Base Future trials should use objective measures of spasticity, longer follow-up, head-to-head comparisons with conventional drugs, and well-documented formulations. Stratified analysis by MS phenotype, disease severity, and prior treatment response would help identify which patients benefit most. Lens takeaway Better trials could clarify which MS patients benefit and when. #### Operationalizing This Evidence in Clinical Practice Before cannabis: Ensure PT, baclofen dose is adequate, tizanidine is optimized, and botulinum toxin has been considered. When using cannabis: Document the specific product, THC:CBD ratio, dose, and route. Establish a baseline spasticity measure and reassess at 2-4 weeks. Lens takeaway Structured implementation maximizes benefit and minimizes harm. #### Integrating Cannabis into MS Care Guidelines This evidence supports cannabis as an option within structured guidelines but not as a standalone or first-line therapy. Clear guidance on formulation, dosing, monitoring, and when to discontinue would help standardize care and reduce confusion. Lens takeaway Policy should support informed use within a comprehensive MS care model. #### Who Benefits and Who Faces Barriers Cannabis products are often expensive and not covered by insurance, limiting access to patients with financial resources. Robust evidence and insurance coverage would improve equitable access. Lens takeaway Advancing evidence and policy can improve fair access to adjunctive therapies. #### Patient-Centered Priorities in Spasticity Care People with MS report that spasticity significantly impacts their daily function, mobility, and quality of life. This review reflects the reality that no single treatment works for everyone. Having options supports personalized care aligned with individual values. Lens takeaway Evidence-based options and shared decision-making improve MS spasticity management. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Cannabinoids+for+Multiple+Sclerosis+Spasticity%3A+2026+Systematic+Review&url=%5Bdraft+URL+pending+publication%5D) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=%5Bdraft+URL+pending+publication%5D) [BlueSky](https://bsky.app/intent/compose?text=Cannabinoids+for+Multiple+Sclerosis+Spasticity%3A+2026+Systematic+Review%20%5Bdraft+URL+pending+publication%5D) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Hamm-Buiar et al., British Journal of Clinical Pharmacology](https://pubmed.ncbi.nlm.nih.gov/42543771/) Related Reading at CED Clinic Continue exploring the evidence Spasticity in MS: Comprehensive Management Overview Clinical context on established MS spasticity management including physical therapy, baclofen, tizanidine, and other approaches. Review MS spasticity management Cannabis for Neurological Conditions: Evidence Review Broader review of cannabis evidence in epilepsy, multiple sclerosis, Parkinson’s disease, and other neurological conditions. Explore cannabis in neurology THC:CBD Ratios and Clinical Effects Why THC:CBD balance matters clinically and what evidence supports specific ratios for different conditions. Learn about cannabinoid ratios ## Frequently Asked Questions What kind of study was this? A systematic review and meta-analysis of 27 randomized controlled trials. It did not conduct new research but synthesized results from existing trials. How many patients were included? Over 3,000 patients across the 27 trials, with varying sample sizes and follow-up durations. What cannabinoid formulations were studied? THC:CBD extracts, isolated cannabinoids (natural and synthetic), other cannabis extracts, and smoked cannabis. THC:CBD combinations showed the most consistent benefit. What was the main outcome? Patient-reported spasticity on various scales. Mean reduction was 0.82 points with THC:CBD extracts compared to placebo. How big is a 0.82-point improvement? Depends on the scale. Most studies used different scales, making absolute comparison difficult. Were side effects reported? Yes. Adverse events were frequent but mostly mild to moderate. Common effects included dizziness, drowsiness, and cognitive changes. Does this mean cannabis is better than baclofen or tizanidine? No. This review did not compare cannabinoids to conventional MS antispasticity drugs. It compared cannabinoids to placebo only. What was the certainty of evidence? LOW, due to heterogeneity in trial design, measurement tools, formulations, and doses. Many trials were small and industry-sponsored. Should I ask my neurologist about cannabis for spasticity? If your spasticity is inadequately controlled by standard therapies, yes—discuss it as a potential adjunctive option with realistic expectations. What research is needed next? Larger, independent trials using objective spasticity measures, consistent cannabinoid formulations, longer follow-up, and head-to-head comparisons with conventional drugs. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).